| abstract |
The present invention relates to novel hepcidine antagonists of the general structural formula, pharmaceutical compositions comprising the same, and the use thereof as medications, particularly for treating iron metabolism disorders, such as in particular iron deficiency diseases and anemias, in particular anemias in conjunction with chronic inflammatory diseases (ACD, anemia of chronic disease, and AI, anemia of inflammation). |